Huntington’s Disease| A Pipeline Analysis Report 2018| Technavio

Technavio has published a new report on the drug development pipeline for Huntington's disease, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced its latest pipeline analysis report on the Huntington’s disease market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat chondrosarcoma.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Huntington’s disease: Market overview

Huntington’s disease is an inherited genetic disorder that causes the death of brain cells. It is highly fatal and causes the progressive breakdown of the nerve cells. Huntington’s disease is inherited from the parents of the patients. Thus, there are chances that the people having Huntington’s disease would have passed the mutated Huntington gene to their children before getting diagnosed.

According to a senior analyst at Technavio for central nervous system, “The symptoms of the disease are usually observed between 30 to 45 years of age. The disease worsens with time, over a period of 10 to 25 years. Huntington’s disease could result in pneumonia, heart failure, and various other complications that could lead to the death of the patient. Over time, the patients start losing the ability to walk, reason, and communicate with others.”

Huntington’s disease: Segmentation analysis

This market research report segments the Huntington's disease market based on therapies employed (monotherapy, combination therapy, and unknown), RoA (oral, intravenous, intrathecal, buccal, subcutaneous, intracerebral, intrastriatal, and undisclosed), therapeutic modalities (small molecules, gene, oligonucleotides, peptide, biological, monoclonal antibody, RNA, stem cell therapy, vaccine, and undisclosed), targets for drugs under development (huntingtin protein, mutated huntingtin gene (mHTT), PDE10, immune system, BDNF, mHTT SNP, others, and undisclosed), MoA (gene therapy, huntingtin protein inhibitor, immunomodulator, PDE10 inhibitor, BDNF modulator, allele-specific silencing, others, and undisclosed), and recruitment status (recruiting, completed, not yet recruiting, active not recruiting, suspended, and undisclosed).

Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 60.38% of the molecules that are being investigated for the treatment of Huntington's disease are monotherapy.

In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About 25% of the total molecules that are in the current pipeline are expected to be administered orally.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for Huntington's disease, including a detailed study of the pipeline molecules.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com